Rafferty Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.69M | Sell |
159,809
-63,934
| -29% | -$3.73M | 0.04% | 251 |
|
|
2025
Q4 | $12.1M | Sell |
223,743
-6,786
| -3% | -$326K | 0.04% | 238 |
|
|
2025
Q3 | $10.4M | Buy |
230,529
+10,678
| +5% | +$499K | 0.03% | 278 |
|
|
2025
Q2 | $10.2M | Buy |
219,851
+26,505
| +14% | +$1.3M | 0.03% | 266 |
|
|
2025
Q1 | $11.8M | Sell |
193,346
-42,928
| -18% | -$2.5M | 0.05% | 234 |
|
|
2024
Q4 | $13.4M | Buy |
236,274
+21,714
| +10% | +$1.21M | 0.05% | 228 |
|
|
2024
Q3 | $11.1M | Sell |
214,560
-15,692
| -7% | -$736K | 0.04% | 273 |
|
|
2024
Q2 | $9.56M | Buy |
230,252
+10,843
| +5% | +$485K | 0.04% | 288 |
|
|
2024
Q1 | $11.9M | Buy |
219,409
+4,148
| +2% | +$211K | 0.04% | 241 |
|
|
2023
Q4 | $11M | Sell |
215,261
-8,779
| -4% | -$461K | 0.05% | 249 |
|
|
2023
Q3 | $13M | Buy |
224,040
+15,770
| +8% | +$966K | 0.08% | 163 |
|
|
2023
Q2 | $13.3M | Buy |
208,270
+14,031
| +7% | +$941K | 0.08% | 157 |
|
|
2023
Q1 | $13.5M | Buy |
194,239
+7,532
| +4% | +$531K | 0.09% | 139 |
|
|
2022
Q4 | $13.4M | Buy |
186,707
+68,983
| +59% | +$5.2M | 0.11% | 141 |
|
|
2022
Q3 | $8.37M | Buy |
117,724
+62,910
| +115% | +$4.56M | 0.09% | 171 |
|
|
2022
Q2 | $4.22M | Sell |
54,814
-18,154
| -25% | -$1.38M | 0.04% | 308 |
|
|
2022
Q1 | $5.33M | Sell |
72,968
-17,007
| -19% | -$1.14M | 0.03% | 376 |
|
|
2021
Q4 | $5.61M | Buy |
89,975
+6,985
| +8% | +$410K | 0.03% | 343 |
|
|
2021
Q3 | $4.91M | Buy |
82,990
+29,273
| +54% | +$1.93M | 0.03% | 306 |
|
|
2021
Q2 | $3.59M | Buy |
53,717
+5,132
| +11% | +$335K | 0.02% | 448 |
|
|
2021
Q1 | $3.07M | Buy |
48,585
+3,373
| +7% | +$210K | 0.02% | 476 |
|
|
2020
Q4 | $2.81M | Sell |
45,212
-1,887
| -4% | -$116K | 0.03% | 356 |
|
|
2020
Q3 | $2.84M | Sell |
47,099
-9,105
| -16% | -$548K | 0.03% | 325 |
|
|
2020
Q2 | $3.31M | Buy |
56,204
+35,997
| +178% | +$2.15M | 0.05% | 247 |
|
|
2020
Q1 | $1.13M | Sell |
20,207
-49,478
| -71% | -$3.02M | 0.05% | 231 |
|
|
2019
Q4 | $4.47M | Sell |
69,685
-464
| -0.7% | -$26.6K | 0.07% | 148 |
|
|
2019
Q3 | $3.56M | Buy |
70,149
+7,108
| +11% | +$334K | 0.06% | 199 |
|
|
2019
Q2 | $2.86M | Buy |
63,041
+57,691
| +1,078% | +$2.69M | 0.05% | 263 |
|
|
2019
Q1 | $255K | Buy |
+5,350
| New | +$267K | ﹤0.01% | 737 |
|
|
2018
Q4 | – | Sell |
-3,335
| Closed | -$207K | – | 629 |
|
|
2018
Q3 | $207K | Buy |
+3,335
| New | +$198K | ﹤0.01% | 674 |
|
|
2017
Q4 | – | Sell |
-47,642
| Closed | -$3.04M | – | 704 |
|
|
2017
Q3 | $3.04M | Buy |
+47,642
| New | +$2.78M | 0.07% | 151 |
|
|
2016
Q3 | – | Sell |
-25,579
| Closed | -$1.88M | – | 487 |
|
|
2016
Q2 | $1.88M | Buy |
+25,579
| New | +$1.81M | 0.13% | 160 |
|
|
2015
Q3 | – | Sell |
-3,527
| Closed | -$235K | – | 552 |
|
|
2015
Q2 | $235K | Sell |
3,527
-324
| -8% | -$21.4K | 0.02% | 483 |
|
|
2015
Q1 | $248K | Buy |
+3,851
| New | +$241K | 0.02% | 489 |
|
Other funds holding BMY
VCM
VPM
Rafferty Asset Management's BMY Position: Q1 2026 in Review
Rafferty Asset Management reduced its Bristol-Myers Squibb (BMY) stake by 29% in Q1 2026, selling an estimated $3.73M and leaving 159,809 shares worth $9.69M. The position accounts for 0.04% of the portfolio, ranked #251.
Rafferty Asset Management first reported a position in BMY in Q1 2015 and has held it in 34 quarters since. The position peaked at $13.5M in Q1 2023. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Rafferty Asset Management held 159,809 shares of Bristol-Myers Squibb worth $9.69M as of Q1 2026.
- Rafferty Asset Management sold 63,934 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.73M.
- Bristol-Myers Squibb made up 0.04% of Rafferty Asset Management's portfolio in Q1 2026, its #251 holding.
- Rafferty Asset Management first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 34 quarters since.
- Rafferty Asset Management's Bristol-Myers Squibb position peaked at $13.5M in Q1 2023.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.